3 ms·

> Production capacity isn't normally the issue for drugs under patent. https://www.fiercepharma.com/pharma/ozempic-shortages-continue-through-q4-novo-and-europ

by rolisz 2y ago

> Production capacity isn't normally the issue for drugs under patent. https://www.fiercepharma.com/pharma/ozempic-shortages-continue-through-q4-novo-and-european-medicines-agency-say https://www.fiercepharma.com/pharma/ozempic-shortages-contin... https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/update-ozempic-supply-remain-limited-2025 https://www.tga.gov.au/safety/shortages/medicine-shortage-al... For one of the most popular drugs in recent years, yeah, production might take some time to ramp up. The issue definitely isn't R&D cost recuperation: in the US Ozempic is much more expensive, but in Romania nobody would pay that much (government or private).

AnthonyMouse 2y ago
> For one of the most popular drugs in recent years, yeah, production might take some time to ramp up. Which is why it's an outlier. > The issue definitely isn't R&D cost recuperation: in the US Ozempic is much more expensive, but in Romania nobody would pay that much (government or private). This has nothing to do with whether the government sets the price. If people in the US would pay $1000 and people in Romania would pay $200 but the government sets the price at $100 in Romania then there is $100 less incentive for R&D.